LL-37 and Autoimmunity: The Double-Edged Sword

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

LL-37, a human antimicrobial peptide, presents a complex and often contradictory role in autoimmune diseases. While it possesses immunomodulatory and anti-inflammatory properties that could be beneficial, its ability to form complexes with self-DNA/RNA and activate immune pathways can also exacerbate conditions like lupus and psoriasis. This 'double-edged sword' nature necessitates a nuanced understanding of its context-dependent effects.

LL-37 and Autoimmunity: The Double-Edged Sword

LL-37, the sole human cathelicidin antimicrobial peptide (CAMP), is a fascinating molecule with a dual identity in the context of immunity and disease. While primarily recognized for its potent antimicrobial activity against bacteria, viruses, and fungi, LL-37 also possesses significant immunomodulatory functions. These immunomodulatory roles, however, present a "double-edged sword" when it comes to autoimmune diseases. Depending on the context, concentration, and specific autoimmune condition, LL-37 can either contribute to immune resolution and tissue protection or act as a pro-inflammatory trigger, exacerbating autoimmune pathology.

What is LL-37?

LL-37 is a 37-amino acid peptide produced by various immune cells (e.g., neutrophils, macrophages) and epithelial cells (e.g., skin, lungs, gastrointestinal tract). It is a key component of the innate immune system, serving as a first line of defense against invading pathogens. Beyond its direct antimicrobial effects, LL-37 influences a wide range of cellular processes, including chemotaxis, angiogenesis, wound healing, and immune cell differentiation.

The Beneficial Edge: LL-37 as an Immunomodulator and Protector:

In certain contexts, LL-37 exhibits properties that could be beneficial in autoimmune settings:

• Anti-inflammatory Effects: LL-37 can modulate inflammatory responses by neutralizing lipopolysaccharide (LPS), inhibiting pro-inflammatory cytokine production, and promoting the resolution of inflammation. For instance, it can suppress the activation of NF-κB, a central regulator of inflammation.
• Wound Healing and Tissue Repair: Its role in promoting angiogenesis and epithelial cell migration is crucial for tissue repair. In autoimmune diseases where chronic inflammation leads to tissue damage, LL-37 could theoretically aid in healing and regeneration.
• Modulation of Adaptive Immunity: LL-37 can influence the differentiation and function of T-cells and B-cells, potentially steering the immune response towards a more tolerogenic profile.
• Clearance of Apoptotic Cells: LL-37 can facilitate the clearance of apoptotic (dying) cells, which is important because uncleared cellular debris can become a source of autoantigens, triggering autoimmune responses.

The Detrimental Edge: LL-37 as a Pro-inflammatory Trigger:

The darker side of LL-37 in autoimmunity stems from its ability to interact with self-components and activate specific immune pathways, particularly in genetically predisposed individuals:

• Complex Formation with Self-DNA/RNA: A critical mechanism by which LL-37 can exacerbate autoimmunity is its ability to form stable complexes with self-DNA and RNA released from dying cells. These LL-37/nucleic acid complexes are highly immunostimulatory.
• Activation of Plasmacytoid Dendritic Cells (pDCs): The LL-37/nucleic acid complexes are efficiently taken up by plasmacytoid dendritic cells (pDCs). Inside pDCs, these complexes activate Toll-like Receptor 9 (TLR9) (for DNA) and TLR7/8 (for RNA), leading to the massive production of Type I interferons (IFN-α).
• Type I Interferon Signature: A prominent Type I interferon signature is a hallmark of several autoimmune diseases, most notably Systemic Lupus Erythematosus (SLE) and psoriasis. The chronic overproduction of IFN-α drives inflammation, promotes the maturation of antigen-presenting cells, and contributes to the breakdown of self-tolerance.
• Psoriasis Pathogenesis: In psoriasis, LL-37 is overexpressed in lesional skin. It forms complexes with self-DNA, activating pDCs and keratinocytes to produce inflammatory cytokines and chemokines, thereby perpetuating the psoriatic inflammatory cycle.
• Lupus Pathogenesis: In SLE, LL-37/DNA complexes are considered key drivers of the disease, contributing to the chronic IFN-α signature and the activation of autoreactive B-cells and T-cells.

Context-Dependent Effects:

The seemingly contradictory roles of LL-37 highlight its context-dependent nature. Its beneficial effects are often observed in acute inflammatory or infectious settings where a rapid, controlled immune response is needed. However, in chronic inflammatory states or in individuals with a genetic predisposition to autoimmunity, its potent immunostimulatory properties, particularly its interaction with nucleic acids, can become pathogenic.

Conclusion and Clinical Implications:

LL-37 is a powerful peptide with significant implications for both innate immunity and autoimmune disease. Its "double-edged sword" nature means that while it holds promise for therapeutic manipulation in some contexts (e.g., enhancing wound healing or fighting infections), it is also a key player in the pathogenesis of others (e.g., lupus, psoriasis). Therefore, direct therapeutic use of LL-37 in autoimmune patients is highly complex and currently not recommended outside of carefully controlled research settings. Future therapeutic strategies might focus on modulating LL-37's activity or blocking its detrimental interactions, rather than direct administration, to harness its beneficial properties while mitigating its pro-autoimmune effects.